Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant gain of 5.40% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 20.20%. Over the past 30 days, the price of ACAD has fallen by 5.11%. And in the last five days, it has fallen by -4.68%.
Acadia Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $26.56 on 02/28/24 and the lowest value was $14.15 on 10/23/24.
52-week price history of ACAD Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Acadia Pharmaceuticals Inc’s current trading price is -27.18% away from its 52-week high, while its distance from the 52-week low is 36.68%. The stock’s price range during this period has varied between$14.15 and $26.56. The Acadia Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.82 million for the day, a figure considerably higher than their average daily volume of 2.51 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Acadia Pharmaceuticals Inc (ACAD) has experienced a quarterly rise of 18.14% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.22B and boasts a workforce of 598 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 17.10, with a change in price of +4.21. Similarly, Acadia Pharmaceuticals Inc recorded 2,055,995 in trading volume during the last 100 days, posting a change of +27.83%.
ACAD’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ACAD stands at 0.06. Similarly, the long-term debt-to-equity ratio is also 0.06.
ACAD Stock Stochastic Average
As of today, Acadia Pharmaceuticals Inc’s raw stochastic average for the last 50 days stands at 69.61%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 49.24%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 40.94% and 46.14%, respectively.
